Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Health indicators

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    75 result(s) found for: Health indicators. Displaying page 1 of 4.
    1  2  3  4  Next»
    EudraCT Number: 2006-004296-35 Sponsor Protocol Number: RGHT000203 Start Date*: 2007-10-18
    Sponsor Name:The Royal Group of Hospitals, Belfast Health and Social Care Trust [...]
    1. The Royal Group of Hospitals, Belfast Health and Social Care Trust
    2. Queen's University Belfast
    Full Title: An investigation into the modulation of obesity associated monocyte/macrophage function, vascular inflammation and insulin resistance by PPAR agonist treatment
    Medical condition: The proposed study will investigate early indicators of cardiovascular disease and diabetes in healthy, obese men without a family history of diabetes and whether these are changed by treatment wit...
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2021-003229-31 Sponsor Protocol Number: CCRG21-001 Start Date*: 2022-12-05
    Sponsor Name:Antwerp University Hospital
    Full Title: Integration of the PD-L1 inhibitor atezolizumab and WT1/DC vaccination into platinum/pemetrexed-based first-line treatment for epithelioid malignant pleural mesothelioma
    Medical condition: Malignant pleural mesothelioma, epithelioid subtype (stage I-IV)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10042613 - Surgical and medical procedures 10046859 Vaccination LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059518 Pleural mesothelioma malignant PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-003823-31 Sponsor Protocol Number: AG348-C-006 Start Date*: 2019-04-08
    Sponsor Name:Agios Pharmaceuticals, Inc.
    Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of AG-348 in Not Regularly Transfused Adult Subjects With Pyruvate Kinase Deficiency
    Medical condition: Pyruvate Kinase Deficiency
    Disease: Version SOC Term Classification Code Term Level
    21.1 10010331 - Congenital, familial and genetic disorders 10037682 Pyruvate kinase deficiency anaemia PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) FR (Completed) PT (Completed) ES (Completed) DK (Completed) NL (Completed) CZ (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2019-004686-41 Sponsor Protocol Number: IBA1160 Start Date*: 2020-12-02
    Sponsor Name:Helsinn Healthcare SA
    Full Title: MyRisk: Efficacy and safety evaluation of oral Akynzeo® in patients receiving MEC at high risk of developing CINV based on a prediction tool. A multinational and multicenter study.
    Medical condition: Patients treated with IV moderately emetogenic chemotherapy and at high risk of chemotherapy induced nausea and vomiting (CINV)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) GR (Completed) CZ (Completed) DE (Completed) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-002470-42 Sponsor Protocol Number: FluSHED-2 Start Date*: 2018-08-30
    Sponsor Name:Imperial College London JRC Office
    Full Title: Assessment of viral shedding week following administration of live attenuated influenza vaccine in children: FluSHED-2 study
    Medical condition: Prevention of influenza infection through immunisation
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004865 10016794 Flu vaccination LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2021-005401-28 Sponsor Protocol Number: AOI2021ME_PICKERING Start Date*: 2022-01-26
    Sponsor Name:University Hospital of Clermont-Ferrand
    Full Title: Effects of the combination of magnesium bisphosphonates versus bisphosphonates alone on bone remodeling: Randomized pilot clinical trial
    Medical condition: postmenopausal osteoporosis
    Disease:
    Population Age: Elderly Gender: Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-001223-13 Sponsor Protocol Number: V58_31 Start Date*: 2014-12-03
    Sponsor Name:Novartis Vaccines and Diagnostics
    Full Title: A Phase III, Observer-blind, Randomized, Controlled, Multicenter Study to Evaluate the Safety of a Trivalent Subunit Influenza Vaccine Produced either in Mammalian Cell Culture or in Embryonated Ch...
    Medical condition: Prophylaxis: Influenza
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2017-003803-22 Sponsor Protocol Number: AG348-C-007 Start Date*: 2018-06-27
    Sponsor Name:Agios Pharmaceuticals, Inc.
    Full Title: An Open-Label Study to Evaluate the Efficacy and Safety of AG-348 in Regularly Transfused Adult Subjects With Pyruvate Kinase (PK) Deficiency
    Medical condition: Pyruvate Kinase Deficiency
    Disease: Version SOC Term Classification Code Term Level
    21.1 10010331 - Congenital, familial and genetic disorders 10037682 Pyruvate kinase deficiency anaemia PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed) DK (Completed) GB (Completed) IE (Completed) IT (Completed) ES (Prematurely Ended) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2017-003916-37 Sponsor Protocol Number: 08448 Start Date*: 2018-04-13
    Sponsor Name:Newcastle Upon Tyne Hospitals NHS Foundation Trust
    Full Title: Multicentre, open label, prospective, single arm study of the safety and impact of eculizumab withdrawal in patients with atypical haemolytic uraemic syndrome
    Medical condition: Atypical Haemolytic Uraemic Syndrome (aHUS)
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2012-004847-61 Sponsor Protocol Number: 008717QM Start Date*: 2013-01-16
    Sponsor Name:Queen Mary University of London
    Full Title: A phase II baseline versus treatment study to determine the efficacy of raltegravir (ISENTRESS) in preventing progression of relapsing remitting multiple sclerosis as determined by gadolinium-enhan...
    Medical condition: Relapsing Remitting Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2018-004842-40 Sponsor Protocol Number: K020-218 Start Date*: 2019-08-21
    Sponsor Name:Kaleido Biosciences
    Full Title: A Phase 2, Open-label Study to Evaluate the Efficacy and Safety of KB195 in Subjects with a Urea Cycle Disorder with Inadequate Control on Standard of Care
    Medical condition: Subjects with a Urea Cycle Disorder with Inadequate Control on Standard of Care
    Disease: Version SOC Term Classification Code Term Level
    20.1 10010331 - Congenital, familial and genetic disorders 10080020 Urea cycle disorder PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed) ES (Prematurely Ended) FR (Prematurely Ended) GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2018-000205-22 Sponsor Protocol Number: CYAD-N2T-005 Start Date*: 2018-06-04
    Sponsor Name:Celyad Onclogy SA
    Full Title: An open-label, Phase I/II study to assess the safety and clinical activity of NKR-2 treatment administration after a non-myeloablative preconditioning chemotherapy in relapse/refractory acute myelo...
    Medical condition: NKR-2 has the potential to treat many distinct tumor-types. This trial will focus on Relapsed and/or refractory (r/r) acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2020-004125-23 Sponsor Protocol Number: CCRG19-002 Start Date*: 2021-05-10
    Sponsor Name:Antwerp University Hospital
    Full Title: Adjuvant dendritic cell immunotherapy complementing conventional therapy for pediatric patients with high-grade glioma and diffuse intrinsic pontine glioma
    Medical condition: Childhood high-grade glioma and diffuse intrinsic pontine glioma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004865 10046859 Vaccination LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006143 Brain stem glioma PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10080666 Diffuse intrinsic pontine glioma LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: BE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2010-023001-36 Sponsor Protocol Number: BAY86-4875/14607 Start Date*: 2011-04-26
    Sponsor Name:Bayer Health Care AG
    Full Title: Multicenter, open-label study to evaluate the safety and efficacy (by blinded reading) of contrast-enhanced magnetic resonance angiography (MRA) after a single intravenous injection of 0.1 mmol/k...
    Medical condition: Subjects with known or suspected vascular disease of the supra-aortic vessels
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10007687 Carotid artery stenosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Completed) SE (Completed) FR (Completed) IT (Completed) PL (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2004-004496-10 Sponsor Protocol Number: NRL011-01/2004 Start Date*: 2005-04-05
    Sponsor Name:Norgine International Limited
    Full Title: A Phase 2a double blind, randomised, placebo controlled, two dose study to determine the effect of orally administered methylnaltrexone (MNTX) in preventing post-operative opiate induced constipati...
    Medical condition: Coated MNTX is being developed for the prevention of constipation in patients taking opioids for hip and knee replacement surgery for analgesia (pain relief). This drug is as yet unlicensed for use...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2021-006810-35 Sponsor Protocol Number: Glioma_Theranostics Start Date*: 2022-11-02
    Sponsor Name:Norwegian University of Science and Technology
    Full Title: 68Ga/177Lu-PSMA theranostics in recurrent grade 3 and grade 4 glioma
    Medical condition: Patients with confirmed recurrent grade 3 and grade 4 glioma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2012-000677-23 Sponsor Protocol Number: CLCL161A2201 Start Date*: 2012-10-24
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A Phase II, multi-center, open-label, neoadjuvant, randomized study of weekly paclitaxel with or without LCL161 in patients with triple negative breast cancer
    Medical condition: Triple negative breast cancer
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Completed) ES (Completed) IE (Completed) IT (Completed) BE (Completed) CZ (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2014-005133-30 Sponsor Protocol Number: V59P14E1 Start Date*: 2014-12-05
    Sponsor Name:Novartis Vaccines & Diagnostics, Inc.
    Full Title: A Phase 3b, Open-Label, Controlled, Multi-Center Study to Evaluate the Persistence Of Antibody Responses Among Children Who Previously Received Novartis MenACWY Conjugate Vaccine.
    Medical condition: Prophylaxis for Neisseria meningitidis serogroup A, C,W-135, and Y.
    Disease:
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2007-007725-46 Sponsor Protocol Number: ASBI 307 Start Date*: 2009-02-06
    Sponsor Name:Asubio Pharmaceuticals, Inc.
    Full Title: A Phase 2b, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Study to Evaluate the Efficacy and Safety of SUN11031 for Injection Administered Subcutaneously Twice Daily for 12 We...
    Medical condition: Cachexia associated with chronic obstructive pulmonary disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Completed)
    Trial results: View results
    EudraCT Number: 2020-006072-32 Sponsor Protocol Number: 2019/ABM/01/00078 Start Date*: 2022-10-05
    Sponsor Name:University Hospital in Poznań
    Full Title: Pulmonary REsistance modification under treatment with Sacubitil/valsartaN in paTients with HeartFailure with reduced ejection fraction
    Medical condition: Heart Failure with reduced ejection fraction.
    Disease: Version SOC Term Classification Code Term Level
    27.0 10007541 - Cardiac disorders 10078289 Heart failure with reduced ejection fraction PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 17 18:45:41 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA